pubmed-article:17001292 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17001292 | lifeskim:mentions | umls-concept:C0010346 | lld:lifeskim |
pubmed-article:17001292 | lifeskim:mentions | umls-concept:C0812246 | lld:lifeskim |
pubmed-article:17001292 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
pubmed-article:17001292 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
pubmed-article:17001292 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
pubmed-article:17001292 | lifeskim:mentions | umls-concept:C0666743 | lld:lifeskim |
pubmed-article:17001292 | lifeskim:mentions | umls-concept:C1706640 | lld:lifeskim |
pubmed-article:17001292 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
pubmed-article:17001292 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
pubmed-article:17001292 | lifeskim:mentions | umls-concept:C0018591 | lld:lifeskim |
pubmed-article:17001292 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
pubmed-article:17001292 | pubmed:issue | 10 | lld:pubmed |
pubmed-article:17001292 | pubmed:dateCreated | 2006-9-26 | lld:pubmed |
pubmed-article:17001292 | pubmed:abstractText | Infliximab, a chimeric anti-tumour necrosis factor (TNF)-alpha antibody induces a clinical response in 70% of Crohn's disease patients and the response to infliximab therapy could be partially determined by genetic factors. The implication of both transmembrane and soluble forms of the TNF-alpha in the mechanism of action of infliximab has been demonstrated. The aim of our work was first to perform a complete study of TNF variants role in the response to infliximab in Crohn's disease. Secondly, considering the role of ADAM 17 in TNF-alpha shedding, the ADAM 17 locus was also studied. The response to infliximab was evaluated in 222 Caucasian Crohn's disease patients with a luminal (n=160) or fistulizing (n=62) form of the disease. Clinical and biological response evaluation was based on the Crohn's Disease Activity Index score and C-reactive protein level evolutions, respectively. The entire TNF gene was sequenced on the complete cohort. Twelve single nucleotide polymorphisms spanning the ADAM 17 locus were studied and haplotypes rebuilt. A clinical response was observed in 64% of the patients and biological response in 77.1% of patients. No association was found between the TNF gene and the response to infliximab. One haplotype in the ADAM 17 region was associated with a clinical response to infliximab in CD patients (adjusted P=0.045). In conclusion, our results exclude, with a reasonable power, an implication of the TNF gene in the response to infliximab in Crohn's disease, but reveal a potential role of the ADAM 17 gene in this response. | lld:pubmed |
pubmed-article:17001292 | pubmed:language | eng | lld:pubmed |
pubmed-article:17001292 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17001292 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17001292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17001292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17001292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17001292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17001292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17001292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17001292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17001292 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17001292 | pubmed:month | Oct | lld:pubmed |
pubmed-article:17001292 | pubmed:issn | 1744-6880 | lld:pubmed |
pubmed-article:17001292 | pubmed:author | pubmed-author:FranchimontDe... | lld:pubmed |
pubmed-article:17001292 | pubmed:author | pubmed-author:RutgeertsPaul... | lld:pubmed |
pubmed-article:17001292 | pubmed:author | pubmed-author:LouisEdouardE | lld:pubmed |
pubmed-article:17001292 | pubmed:author | pubmed-author:De... | lld:pubmed |
pubmed-article:17001292 | pubmed:author | pubmed-author:FarnirFrédéri... | lld:pubmed |
pubmed-article:17001292 | pubmed:author | pubmed-author:BelaicheJacqu... | lld:pubmed |
pubmed-article:17001292 | pubmed:author | pubmed-author:BoursVincentV | lld:pubmed |
pubmed-article:17001292 | pubmed:author | pubmed-author:VermeireSéver... | lld:pubmed |
pubmed-article:17001292 | pubmed:author | pubmed-author:Van... | lld:pubmed |
pubmed-article:17001292 | pubmed:author | pubmed-author:DidebergVinci... | lld:pubmed |
pubmed-article:17001292 | pubmed:author | pubmed-author:ThéâtreEmilie... | lld:pubmed |
pubmed-article:17001292 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:17001292 | pubmed:volume | 16 | lld:pubmed |
pubmed-article:17001292 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17001292 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17001292 | pubmed:pagination | 727-34 | lld:pubmed |
pubmed-article:17001292 | pubmed:meshHeading | pubmed-meshheading:17001292... | lld:pubmed |
pubmed-article:17001292 | pubmed:meshHeading | pubmed-meshheading:17001292... | lld:pubmed |
pubmed-article:17001292 | pubmed:meshHeading | pubmed-meshheading:17001292... | lld:pubmed |
pubmed-article:17001292 | pubmed:meshHeading | pubmed-meshheading:17001292... | lld:pubmed |
pubmed-article:17001292 | pubmed:meshHeading | pubmed-meshheading:17001292... | lld:pubmed |
pubmed-article:17001292 | pubmed:meshHeading | pubmed-meshheading:17001292... | lld:pubmed |
pubmed-article:17001292 | pubmed:meshHeading | pubmed-meshheading:17001292... | lld:pubmed |
pubmed-article:17001292 | pubmed:meshHeading | pubmed-meshheading:17001292... | lld:pubmed |
pubmed-article:17001292 | pubmed:meshHeading | pubmed-meshheading:17001292... | lld:pubmed |
pubmed-article:17001292 | pubmed:meshHeading | pubmed-meshheading:17001292... | lld:pubmed |
pubmed-article:17001292 | pubmed:meshHeading | pubmed-meshheading:17001292... | lld:pubmed |
pubmed-article:17001292 | pubmed:year | 2006 | lld:pubmed |
pubmed-article:17001292 | pubmed:articleTitle | The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. | lld:pubmed |
pubmed-article:17001292 | pubmed:affiliation | Department of Human Genetics, Centre for Biomedical Integrated Genoproteomics, University of Liège, Liège, Belgium. vinciane.dideberg@chu.ulg.ac.be | lld:pubmed |
pubmed-article:17001292 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17001292 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17001292 | lld:pubmed |